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background:  Transcatheter aortic valve replacement (TAVR) was recently introduced as viable option for patients with severe aortic 
stenosis and at high risk for surgical replacement.
methods:  TAVR implants (n=23) from the CoreValve US Pivotal Trial of extreme- and high-risk patients (mean age 82.9±9.9 years, 48% 
males) were examined at autopsy. Survival was stratified by time (<30; 30 to 90; and >90 days). Whole hearts / valve explants were 
radiographed and scanned by micro CT. Paravalvular gaps (PG) were noted and valve leaflets were removed for paraffin processing while 
the frame was sectioned at the inflow, native aortic valve, and outflow region. Valve components were independently reviewed and scored 
for thrombus, inflammation, neointima, degeneration, and calcification.
results:  Mean implant duration was 90.7 ±176.6 days. Causes of death < 30 days were deteriorating heart failure (HF) in 6/11 (55%), 
myocardial infarction (MI) in 2/11 (18%), valve thrombosis 2/11 (18%) and procedural in 1/11 (9%). At 30 to 90 days, HF was noted in 5/7 
(71%) and MI in 2/7 (29 %) patients. At >90 days, HF was confirmed in 4/5 (80%) while a single valve showed endocarditis (20%). PG were 
noted at 30 days and absent >90 days. No fractures of the valve frame were observed. Thrombi were greatest at 90 days and declined 
thereafter while neointimal coverage increased over time peaking at 90 days (score by duration 0 vs. 2 vs. 2.7, p<0.01). Inflammation 
increased up to 90 days and thereafter plateaued. Neointimal thickening of leaflets increased over time and peaked at 90 days (score 
by duration 0.006 vs. 0.34 vs. 0.42, p<0.0001). Structural leaflet changes were minimal for all devices. Three valves however, exhibited 
thrombosis with embolic complication in two. Leaflets inflammation was minimal and peaked at 90 days.
Conclusion:  Heart failure was the primary cause of death in patients with CoreValve TAVR. The decline in clinically observed paravalvular 
leaks over time was also confirmed at autopsy. Neointimal coverage over frame and leaflets peaked at 90 days, while inflammation and 
leaflet degeneration were minimal. The current histopathologic data supports the encouraging clinical performance of CoreValve.
